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ABSTRACT 
 
Modifying substrate specificity of β-glucuronidase (GUS) would be helpful in various enzyme 
prodrug systems in delivering drug dose to the site of action in the cancer treatment. Due to the 
presence of endogenous enzyme in human tissues, GUS-based Antibody-Directed Enzyme 
Prodrug Therapy (ADEPT) requires a novel substrate to avoid undesirable systemic activation. 
GUS is a glycosyl hydrolase, highly specific towards the glucuronide derivatives. It catalyzes the 
glycosidic cleavage of β-D-glucuronides to β-D-glucuronic acid and aglycone moiety. In order to 
gain insight on the substrate specificity of GUS, C6 carboxyl group of glucuronic acid was 
modified to C6 carboxamide (amide derivative). We have examined amide derivatized substrates 
with a variety of different aglycone groups including p-nitrophenyl, phenyl and 4-
methylumbelliferone to further probe the activity profile of GUS. In an effort to optimize GUS 
activity, docking studies have been performed which indicated that amino acid point mutations 
near C6 carboxyl group of glucuronic acid could improve binding of the derivatized substrates. 
As a result point mutations to Arg-562 and Lys-568 which make the active site less positively 
charged either by glutamine or glutamate lead to an enzyme with much lower native substrate 
activity but abolished activity for the amide-derivatized substrate. This research study showed 
that there is still a further need of finding appropriate mutations required to make glucuronamide 
a better substrate for the mutated version of GUS.  
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1 INTRODUCTION 
1.1 Targeted Cancer Therapy  
Chemotherapy is often associated with cytotoxic side effects due to the nature of 
medicinal agents. Premature termination of chemotherapy often results due to the intolerable side 
effects. The majority of these medicinal agents lack the ability to discriminate between normal 
and cancerous cells. As a result, drug-induced toxicity prevents achieving effective therapeutic 
drug concentration at cancer tissues. Due to physiological similarities between normal and tumor 
cells, the clinical efficacy of most anti-tumor drugs is limited by concentration-dependent 
systemic toxicity
1
. The development of improved methods for selective delivery of medicinal 
agents for cancer treatment is an active area of research
1
. Selective targeting of cancer cells with 
potent drug molecules enables better efficacy of the treatment and reduces side effects due to less 
exposure of drug dose to the patient. There are a variety of cancer treatments involving targeted 
drug delivery systems such as liposomes, nanoparticles, dendrimers, polymersomes and carbon 
nanotubes utilizing cell surface receptors like transferrin, lactoferrin, folate,  and human 
epidermal growth receptors (EGFR) to the tumor cells
2
. One way is to administer an inactive 
form of the drug which is referred to as prodrug (less toxic). This prodrug is only converted in to 
a potent active drug form through enzymatic reaction when it is near the tumor site with the aid 
of enzyme conjugated delivery system
3
.   
1.2 Enzyme Prodrug Delivery Systems 
Enzyme prodrug delivery systems selectively activate prodrugs through enzymes which 
include systems like Antibody Directed Prodrug Therapy (ADEPT), Virus Directed Prodrug 
Therapy (VDEPT), and Gene Directed Prodrug Therapy (GDEPT)
4
. These delivery systems 
either involve selected enzyme accumulation in the tumor by directing the enzyme or enzyme 
expression in the tumor cells through targeted gene therapy.  
1.2.1 Gene Directed Enzyme Prodrug Therapy (GDEPT) 
 GDEPT is a gene therapy based on introduction of DNA into the cells. Gene therapy involves 
viral and non-viral insertion of DNA into cells.  It mainly aims on enzyme gene sequence. The 
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gene sequence is first introduced in the cancer cells via gene therapy
5
. Once the gene is 
introduced into the tumor cells, it results in subsequent enzyme expression. Successful enzyme 
expression is followed by prodrug administration to the patient. The enzyme specific to prodrug, 
activates the prodrug at the site of action. There are a variety of enzymes that have been used in 
GDEPT like cytosine deaminase
6
, carboxypeptidase G2
7
, and CYP450
8
. The major challenge in 
GDEPT is low gene transfer rate specifically to tumor cells in vivo, poor enzyme expression and 
low efficiency in terms of gene expression, and other problems like local infection and tumor 
nodule ulceration
4, 9
.  
1.2.2 Virus Directed Prodrug Therapy (VDEPT) 
VDEPT involves viral vectors for introducing enzyme gene sequence into the tumor cells
4
. In 
other words, it is also known as Virus Based Gene Therapy
10
. Various adenoviral and retroviral 
vectors have been studied to optimize conditions for VDEPT
11
. One of the trials showed reduced 
tumor growth in vitro and in vivo using human type-5 adenovirus vector for expressing purine 
nucleoside phosphorylase, along with hormonal therapy
12
. The limitations of using adenovirus 
vectors is, they transduce both dividing and non-dividing cells, while retroviral vectors targets 
specifically to dividing cells
4
. Considering slowly dividing human tumor cells, retroviral vectors 
showed poor transduction rate for tumor targeting
13
.  The main limitations of these vectors 
include immunogenicity, insertional mutagenesis to host cell DNA, and low transduction rate. As 
a result, these methods are still struggling to meet their objectives due to low transduction rate, 
results in poor enzyme expression in tumor cells
4, 9
. 
1.2.3 Antibody Directed Enzyme Prodrug Therapy (ADEPT) 
  The tumor antigen-specific delivery system involves an antibody–enzyme (Ab-Enz) 
conjugate, where the antibody is specific to an antigen expressed by tumor cells
14
.  The enzyme 
specific to the prodrug, catalyzes the reaction. This results in the release of active drug near 
tumor cells. ADEPT involves a four step process (Fig 1.1) for which the first step is 
administration of an Ab-Enz conjugate to the patient. After binding of the conjugate to the tumor 
expressing the antigen, in step 2 excess Ab-Enz must be excreted prior to the next step in vivo. 
Prodrug is then administered in step 3 and become selectively activated (active form) at the site 
of the tumor by the enzymatic catalysis in step 4
3, 15
 (Fig 1.1).  The important feature of ADEPT 
is that it increases the active drug concentration near tumor vicinity which kills the tumor cells. 
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Major limitations that ADEPT is facing are immunogenicity issues of Ab-Enz conjugates, 
preactivation of prodrug and poor efficacy, which will be briefly discussed in later part of this 
thesis. Like other enzyme prodrug systems, ADEPT also struggling to fulfill its objectives so far. 
In order to optimize ADEPT and improve its efficacy, each component of it needs to be 
optimized. In this research a long term goal is to apply our basic research to an ADEPT system. 
 
Figure 1.1 Overview of steps involved in ADEPT: (1) Ab-Enz conjugate is administered 
initially,  (2) Ab-Enz binds to the specific to tumor antigen, (3) Prodrug is administered to the 
patient,  (4) Prodrug  is activated at the site of action 
1.3 ADEPT Antibodies 
  Fundamental to the ADEPT approach is the specificity which exists between an antibody and 
its antigen. This is an important tool in cancer treatment
16, 17
. Monoclonal antibodies (mAbs) 
have been used for selective delivery of therapeutics against a particular tumor antigen and play 
a potential role for their use as delivery vehicles in bioactive or diagnostic agents. There are a 
number of different antibodies that are approved by FDA for various cancer types including 
Trastuzumab for breast cancer, Cetuximab and Bevacizumab for colorectal cancer, Ibritumomab 
tiuxetan and Rituximab for non-Hodgkin’s lymphoma, Gemtuzumab ozogamicin for acute 
myelogenous leukemia, and Alemtuzumab for chronic lymphocytic leukemia
1, 16, 18
. Promising 
good results have been achieved by using mAbs in case of haematopoietic melignancies like 
non-Hodgkin’s lymphoma1. The human epidermal growth receptors (EGFR/ HER) are expressed 
in various types of cancers, including breast cancer
18
. As overexpression of HER-2 in breast 
cancer is prominent, Trastuzumab (first anti HER2 mAb) showed promising results for 
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ADEPT
19, 20
.  Some of limitations that do come across optimizing ADEPT system are, large size 
of antibodies, which leads to poor penetration of the conjugate in the tumor, and high 
intratumoural pressure which also acts as barrier for the conjugate to attach to the tumor
1, 19
. A 
recent study suggests that patients develop resistance against Trastuzumab for anti-HER2 
treatment and there are several factors like angiogenesis, endocrine resistance, cell cycle 
regulators and other HER2 inhibitors that needs to be considered for optimizing anti-HER2 
treatment
19, 20
. 
1.4 ADEPT Enzymes 
 The enzymes employed for prodrug activation conversion are fundamental to the ADEPT 
approach. In the literature to date, various enzymes have been examined including both 
mammalian and non-mammalian sources such as nitroreductase
21
, carboxypeptidase A
22, β-
lactamase
23
, cytosine deaminase
13
, carboxypeptidase G2
24
, β-glucuronidase25, alkaline 
phosphatase
26, α-galactosidase27 and penicillin G amidase28. Enzymes from non-mammalian 
origin, prevent the unwanted activation of the prodrug by endogenous enzymes and catalyze the 
reaction more specifically to the tumor site. There are no post translational modification issues 
such as glycosylation and high scale production makes it easy to use
29
. A major disadvantage of 
using non-mammalian enzymes is elicitation of an immune response
30, 31
. In the case of 
mammalian enzymes, the potential chance for immune response is reduced but endogenously 
expressed enzyme can reduce specificity through systemic activation as a result preactivation of 
prodrug occurs resulting in failure of targeted drug delivery, loss of effective drug therpeutic 
index and side effects due to toxicity of drug to normal cells.  Enzymes from non-mammalian 
sources which have mammalian homologues have been used such as β-glucuronidase, 
carboxypeptidase A and nitroreductase. Due to their non-mammalian origin, there will always be 
chances of an immune response. In case of Human β-glucuronidase (GUS), it is expressed 
endogenously and so is present in low levels in blood. Human GUS is less catalytic efficient 
compared to its bacterial form
29
. The optimum pH of Human GUS (pH range 4-5)
32
 and bacterial 
GUS (pH range 5-7)
33
 differ greatly. Human GUS (lysosomal acid hydrolase) exhibited only 
10% activity at physiological pH
34
. Considering nitroreductase (NR), Human NR uses a different 
substrate compared to bacterial NR
29
. 
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 One of the clinical trials of ADEPT for colorectal cancer used caboxypeptidase G2 to activate 
a prodrug (bis-iodo phenol mustard, ZD2767P) and showed remarkable site specificity, giving 
tumor to blood ratios of antibody-enzyme conjugate (>10000 : 1), with few side effects 
24
. Use of 
Ab-Enz conjugates with prodrugs showed promising results such as using glucuronylated 
Doxorubicin (DOX-GA3) as prodrug and Ab-Enz conjugate as 323/A3-mGUS using β-
glucuronidase, demonstrated strong antitumor effect resulting growth inhibition of 93%
25
. 
GUS has been tested with glucuronide derivatives of a variety of drugs like doxorubicin
25
, 9-
amino-camptothecin
35
, Epirubicine
36
 and Aniline-mustard
37
 as prodrugs and showed promising 
results and reduced systemic toxicity
38
. As GUS is present in human blood and tissues, there is 
potential for systemic activation of the prodrug 
39
. There are a limited number of attempts carried 
out in the case of breast cancer
40
 and various other studies done on cancer are still struggling to 
meet their objectives
41
. 
 In most of the trials and studies for ADEPT, there were problems related to the side effects 
due to non-specificity of human enzyme analogues or immunogenicity issues associated with the 
use of enzyme of non-mammalian origin
42
. Bacterial enzymes that have no human analogue 
could provide high specificity and provide the advantage of higher turnover rates. 
1.4.1 β-Glucuronidase 
 β-Glucuronidase (GUS, EC 3.2.1.31) is a type 2 glycoside hydrolase that catalyzes the 
cleavage of β-glucuronides43. The enzyme is highly specific for the carbohydrate moiety of the 
glucuronide substrate, while almost any aglycone moiety (or drug) can be conjugated to β-D-
glucuronide moiety at C-1 hydroxyl (Scheme 1).  
 
 
 
 
Scheme 1 Hydrolysis of β-D-glucuronide derivative 
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Figure 1.2 Structure of substrate and non-substrate of GUS. The compound on the left is 
BA3GN is a substrate for GUS while the compound on right is BA3GNamide is not a substrate. 
 GUS is highly active towards the C6 carboxylic acid of glucuronide moiety substrates, 
although it showed very reduced activity with galacturonide (C4 hydroxyl in opposite 
orientation), glucoside (C6 hydroxymethyl), galactoside (C4 hydroxyl in opposite orientation 
with C6 hydroxymethyl) and mannoside (C2 hydroxyl in opposite orientation)
44
. The reason 
behind high activity of GUS towards glucuronide moeities could be the putative negative charge 
of the C6 carboxyl group ionic interaction by positively charged residues
45
. The specificity of 
GUS towards the C6 carboxyl group makes it more specific for glucuronide derivatives. The 
glucuronamide that is not a substrate for GUS is Benzyladenine N3-glucuronamide 
(BA3GNamide). BA3GNamide was made from Benzyladenine N3-glucuronide (BA3GN) 
compound where the carboxylic acid was replaced by an amide group (Fig 1.2)
46
. 
1.4.2 Mechanism  
 The catalytic mechanism for GUS is a two-step process involving the formation and 
hydrolysis of a covalent glucuronyl-enzyme intermediate via oxacarbenium ion-like transition 
states
47
.  In case of Escherichia coli (E. coli) GUS, the two catalytically important residues are 
E413 and E504, of which E504 acts as the catalytic nucleophile, while E413 act as a general 
acid/base (Scheme 2). In the first step of glucuronylation, E504 attacks at the C1 anomeric 
carbon, this leads to the release of the aglycone moiety with protonic assistance of E413, forming 
a glucuronyl-enzyme intermediate. In the second step, deglucuronylation proceeds via 
hydrolysis, where a water molecule acts as a nucleophile with base assistance of E413. This 
leads to the release of the glucuronic acid and returns the enzyme to its original state. 
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Scheme 2 Mechanism of β-glucuronidase 48. 
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1.4.3 GUS from Plants, animals and microorganisms 
GUS catalyzes the reaction to give glucuronic acid, which is the fundamental component of 
proteoglycans like heparan sulphate, chondroitin sulphate, dermatan sulphate and hyluronan in 
animals while arabinogalactan in higher plants
49
.  
GUS is classified into three glycoside hydrolase (GH) families, GH1, GH2 and GH79, based on 
the amino acid sequence in the Carbohydrate-Active-Enzymes (CAZy) database 
(http://www.cazy.org/Glycoside-Hydrolases.html). No GUS from GH2 family or similar 
sequence have been found in plants
49
. The first ever GUS structure that was crystallized and 
solved was human GUS
50
 followed by E. coli GUS
51
. E. coli and Human GUS structures belong 
to the GH2 family which reveals high sequence similarity.  
E. coli GUS is a cytoplasmic enzyme with a broad pH range (pH 5.0 - 7.5)
33
. It exists as a 
homotetramer containing active site residues at the tetramer interface in a large cleft at the 
interface of two monomers with a monomer weight of 68 kDa 51, 52. One of the attractive features 
for using E. coli GUS in ADEPT is its ability to tolerate large amino terminal fusions without 
loss of enzyme function and stability
33, 53
.  E. coli GUS is also thermotolerant and resistant to 
many proteases
33, 53
, which would be helpful in utilizing GUS in ADEPT. 
Human GUS catalyzes degradation of glucuronic acid containing glucosaminoglycans like 
heparan sulphate, chondroitin sulphate, dermatan sulphate
54
 and in proteoglycan degradation of 
lysosomes
55
. Lysosomes are membrane bound vacuoles responsible for digesting biomolecules 
such as sugars and proteins. As with E. coli GUS, its active form is a homotetramer where each 
monomer is 75-83 kDa
32, 56
. Deficiency of Human GUS leads to mucopolysaccharidosis Type 
VII which results in accumulation of mucopolysaccharides in body tissues
57
. After the 
glycosylation at N-glycosylation sites in the endoplasmic reticulum and Golgi complex, it is 
directed to lysosomes via mannose-6-phosphate receptor
58, 59
. The pH optimum for Human GUS 
is in the range of 4-5
32, 60
, which is low compared to pH range of E. coli GUS, which suggests 
low turnover rate of Human GUS at physiological pH. It also possess thermotolerance and 
stability
32
. No cooperative binding in both E. coli and Human GUS has been reported yet.  
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1.4.4 Structural Features 
 The structure of Human and E. coli GUS both have been solved through X ray 
crystallography
50, 51, 61
. Human GUS was crystallized a decade ago, while E. coli GUS was 
crystallized recently and showed an overall 50% sequence similarity
50
 (Fig 1.3) and were 
structurally very similar (Fig 1.4).  
  
Figure 1.3 Sequence alignment of E. coli GUS and human GUS  
Sequence alignment  was performed by using ClustalW 
62
,Blosum scoring matrix
63, 64
 and ESPript V2.2
65
 Amino 
acids represented with white letters in red background are identical residues, while red letters represents similar 
residues. Secondary structures of E. coli GUS and Human GUS crystal structure are displayed above and below the 
sequence alignment respectively. Blue starred residues represent the conserved catalytic residues. 
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The overall structure contains two domains where the C-terminal domain forms the α/β- or TIM 
barrel motif containing the active site residues, and the  N-terminal domain resembling the sugar 
binding motif of family 2 glycosyl hydrolases
51
. The active site residues in E. coli GUS are E504 
and E413, respectively which corresponds to E540 and E451 in Human GUS. Additionally the 
region between the N- and C-terminal domains exhibit an immunoglobulin like β-sandwich 
domain consistent with other family 2 glycosyl hydrolases 
66
. 
Superimposing Human and E. coli GUS structure reveals a 1.4 Å root mean square deviation 
(rmsd) over 565 equivalent Cα positions51.  Interestingly the E. coli GUS structure contains a 17-
residue “bacterial loop”, not found in the human GUS. A recent study showed that, the bacterial 
loop is highly important for higher activity of GUS as well as for selective inhibition
61
.    
 So far, there have been crystal structures of GUS with inhibitors, but no GUS structure with 
substrate or product has been crystallized yet. In an E. coli GUS, each active site contains two 
bacterial loops, one from the same monomer while other from the neighboring monomer (Fig 
1.5)
51
. 
 
 
Figure 1.4 Structural comparison of GUS: Superposition of E. coli (blue, PDB 3K4D) and human 
GUS (green, PDB 1BHG) shows similar structures. E. coli GUS bacterial loop is represented in red color. 
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Figure 1.5 Active site of E. coli GUS showing active site residues along with bacterial loop. 
Bacterial loop monomer 1 is from the same monomer with the catalytic residues. 
 
 
Figure 1.6 The active site of E. coli (blue) and human GUS (green) are very similar and 
identical residue composition. Residues numbers represents the E. coli GUS species. 
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The importance of the C6-carboxyl group of glucuronic acid was shown to interact with residues 
D163, Y468, E504, Y549, R562, N566, and K568; which are highly responsible for substrate 
recognition and binding
44
. The residues lining the active site within Human and E. coli GUS are 
identical and have very similar orientations (Fig 1.6). 
From the structural studies of inhibitor binding to E. coli GUS and modeling study on 
Human GUS using glucuronic acid, the C-6 and C-2 β-D-glucuronide positions are highly 
important for determining substrate binding specificity
44, 51
.  
 
Figure 1.7 Docked glucuronic acid (green) moiety in the active site of E. coli GUS (PDB: 
3K4D) showing important residues responsible for recognition. The docking studies for 
substrate binding were performed with GOLD Suite software package67. 
Docking studies have been performed in our laboratory by Dr. Sean Dalrymple and they 
reveal pose predictions with active site residues Y472, K568, R562, D163 and N566 forming 
hydrogen bond with C-6 carboxylate group while residues W549 and D163 form hydrogen 
bonds with the C-4 hydroxyl group (Fig 1.7). It has been proposed that positively charged 
residues K568 and R562 are important for stabilizing the C-6 carboxylate group through ionic 
contributions. 
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1.5 Hypothesis 
As GUS is highly specific towards glucuronide substrates, we will use structure based design to 
alter the enzyme substrate specificity for accepting amide-derivatized substrate. A research study 
showed that the mutations in the active site have changed the substrate specificity of GUS to β-
galactosidase
44
. In conjunction to this study, there are other studies that confirm that substrate 
specificity of GUS can be modified
68
. Further, there are two separate studies done on GUS 
showed that with the help of mutations optimum pH can be altered
39
 and thermo stability can be 
improved
52
 .  
The implementation of structure based design to re-engineer GUS substrate specificity through 
point mutations for a modified substrate will result in avoiding undesirable substrate catalysis by 
native GUS (Fig 1.8). 
 
 
 
Figure 1.8 Re-engineering of GUS based ADEPT. (Top) Native GUS substrate selectivity, (middle) Re-
engineered GUS-substrate selectivity, (bottom) Native GUS does not recognize modified substrate. 
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1.6 Research Objectives 
The objectives in this research study are: 
 
(1)  Evaluate E. coli GUS substrate specificty towards glucuronide and glucuronamide 
derivatives. 
(2) Re-engineering E. coli GUS substrate specificity through point mutations – to recover 
binding of glucuronamide as substrate 
 
In order to gain insight into the substrate specificity of E. coli GUS and to recover activity for 
amide derivatized (carboxamide) substrate, mutations will be performed near the C6 carboxyl 
group to further explore the substrate specificity for an amide-derivatized substrate. The aim is 
for only the mutated version of GUS to be able to recognize the modified (amide-derivatized) 
substrate not the native enzyme. 
 We will test this modification with different aglycone moieties and kinetics will be performed 
to observe the changes in kcat and Km. The best modified substrate by hypothesis would have 
poor or no binding (typically represented by high Km values) and very low or no turnover rate 
(low kcat values) for the native GUS and vice versa for the mutated enzyme. 
The C6 carboxyl group of glucuronic acid is negatively charged and is highly important 
for substrate recognition. It has been proposed that utilizing this negative charge from the protein 
side, by making active site more negatively charged by mutations to the residues responsible for 
interacting with the C6 carboxyl group of glucuronic acid to block substrate recognition
44
. As a 
previous study showed glucuronamide is not a substrate for GUS suggesting C6 position 
modification to neutral carboxamide would be one way to proceed
46
.  As such, it is important to 
obtain high quality protein which is suitably stable for the kinetic assaying procedure.  Towards 
this goal, we attempted to optimize the currently employed protein purification procedure. Site 
directed mutagenesis will further explore the substrate selectivity towards synthetic substrates. 
These mutations will aid in further determination of residues involved in substrate recognition, 
specifically towards C6 carboxyl group. Efforts will be made to change substrate selectivity 
through point mutations, with the goal that only the mutated form of GUS will catalyze the 
reaction, not the wild type enzyme. Circular dichroism will be employed to study protein 
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secondary structures and will aid in the comparison of wild type enzyme with its mutated 
analogues. Isothermal titration calorimetry will be used to explore ligand binding property with 
both wild type and mutated enzymes. These techniques will be helpful in determining substrate 
binding ability with the enzyme and would be helpful in determining a better substrate. Our 
efforts will be optimizing the conditions for mutated enzyme to efficiently catalyze a reaction for 
an amide-derivatized substrate. Initial studies will be performed on E coli GUS as working with 
a bacterial strain is comparatively easier than eukaryotic strain in terms of protein expression. 
One of the long term goals also include changing the pH optimum of human GUS.  
Ultimately once the structure based redesign approach is established, the principles will be 
translated to Human GUS to reduce the chance of immunogenic response for ADEPT.  This will 
differentiate the mutated version of enzyme from the rest of endogenous enzymes. Once this 
mutated enzyme is in conjugation with the respective antibody, it will serve the purpose of 
selective drug targeting, minimizing side effects and improves the efficacy of the ADEPT 
system. 
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2 EXPERIMENTAL METHODS 
2.1 Chemical Reagents 
 
 p-Nitrophenyl-β-D-glucuronide (PNPG), 4-methylumbelliferyl-β-D-glucuronide (MUG), and p-
nitrophenyl-β-D-Glucopyranoside were purchased from Sigma Adlrich, Thiophenyl-β-D-
Glucuronide (PGS) was obtained from Gold Biotechnology St. Louis Mo. 
p-Nitrothiophenyl-β-D-glucuronide (PNSPG), Phenyl-β-D-glucuronide (PG), p-nitrophenyl-β-D-
glucuronamide (PNPGun), Phenyl-β-D-glucuronamide (PGun), and 4-methylumbelliferyl-β-D-
glucuronamide (MUGUN) were synthesized by Dr. Rajendra Jagdhane in laboratory of Dr. 
David Palmer. QAIprep Miniprep kit was purchased from QIAgen. Restriction enzyme and 
markers were obtained from Biolab New England and Sigma Aldrich respectively. Pfu DNA 
polymerase was purchased from Agilent. Protease inhibitor cocktail (EDTA free) was obtained 
from Thermo Scientific. Primers were synthesized by Alpha DNA. Other chemical reagents were 
of the highest quality grade purchased from Sigma-Aldrich Inc. 
2.2 Equipment and software used in various experiments 
 
 All the kinetic measurements were performed on Varian Cary 50 - UV spectrometer while 
fluorescence based enzyme assays were performed on PTI fluorospectrometer. Initial docking 
studies were done using Gold suite software 
67
. Carywin UV and Graphpad prism (Version 3.0) 
software were used for determining kinetic parameters. PCR reactions were performed on 
PTC
TM
 100 (Programmable thermal controller) under Program Anidko. Centrifugation was 
performed using Beckman Coulter Microfuge 18 and a Beckman J2-HS refrigerated centrifuge 
equipped with JA-25.50 rotor. For incubation and shaking, Innova 4230 refrigerated 
incubator/shaker was used. Cell lysis was performed using Virsonic 600 Ultrasonic Cell 
Disrupter. His GraviTrap
TM
 hand columns and Superdex 200
TM
 (gel filtration) column both from 
GE healthcare were used for protein purification, the later column was used with a BIO-CAD 
700E, High Fast Protein Liquid Chromatography Workstation. Protein concentration was 
determined by NanoDrop® ND-1000 and analyzed by SDS-PAGE; Gel casting units were from 
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Hoefer Scientific. Barnstead NANOpure
®
 DIamond
TM
 (UV/UF) Ultrapure water system in all 
experiments. Cicular Dichroism studies were performed on PiStar-180 instrument manufactured 
by Applied Photophysics. CDNN deconvolution program 
69
 provided by Saskatchewan structural 
sciences centre was employed for determining spectra details. ITC experiments were performed 
on Nano ITC by TA Intruments Microcalorimetry. ITC data were analyzed by Nano Analyze 
software provided by TA instruments. 
2.3 Plasmid Isolation, Growth and Transformation  
 
 Plasmid DNA from E. coli cells was isolated using QIAprep Miniprep kit protocols. The 
pHISTEV-GUS was prepared by Dr. Inder Sheoron (Department of Chemistry, University of 
Saskatchewan, Saskatoon (SK) Canada). Recombinant plasmid (10 µL) was transformed in to 
the DH5α competent cells (50 µL) and incubated for 30 min on ice; heat shocked for 45 s at 
42˚C and then 2 min on ice. The transformation mixture was then added to 0.5 mL of LB media 
and incubated for 1 hour at 37˚C with shaking at 250 rpm. Cells were spun down for 3 min at 
13000 rpm on the bench top centrifuge and 400 µL of the supernatant was then discarded. The 
cells were resuspended in remaining LB media and plated on agar plates containing kanamycin 
(50 µg /mL). Agar plates were incubated for 16 hrs at 37˚C. Single colonies were selected and 
grown in 4 ml LB media containing kanamycin (50 µg/mL). The plasmid DNA was isolated as 
described above and sequenced at NRC Plant Biotechnology Institute. Successful recombinant 
plasmids were expressed using the T7 promoter system transformed into E. coli BL21-gold cells.  
 
2.4 Protein production and purification 
 
 A single colony containing recombinant plasmid was inoculated in 4 mL LB media containing 
kanamycin (50 µg/mL) and incubated at 37˚C and 250 rpm overnight. A 1 ml aliquot of the 
overnight culture was used to inoculate 100 mL LB containing kanamycin (50 µg/mL) which 
was then incubated at 37˚C, 250 rpm overnight. A 10 mL aliquot of overnight culture was used 
to inoculate 1L LB containing kanamycin (50 µg/mL) and incubated at 37˚C and 250 rpm. The 
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expression was induced with IPTG (final concentration 0.2 mM) when OD600 reached 0.6. The 
cell culture was incubated at 15˚C for 15 hrs at a rotation speed of 250 rpm. The cell culture was 
then centrifuged in Sorvall Legend RT benchtop centrifuge at 3650 rpm for 20 min at 4˚C and 
the supernatant discarded. From 1L cell culture, 8 g (wet weight) cells were obtained. Cell pellets 
were placed in -80 ˚C for storage.  
 The obtained cell pellets was resuspended in 20 mL binding buffer (25 mM imidazole, 20 mM 
potassium phosphate, 500 mM NaCl, pH 7.4), and then lysozyme (0.5 mg/mL), DNAse (1 
µg/mL), AEBSF (0.05 mg/mL) and protease inhibitor cocktail (100 µL/10 mL lysate) were 
added and stirred for 30 min. The sample was then sonicated for 3 min with 15s on/off intervals 
and the supernatant was separated from cell debris by centrifugation in Beckman J2-HS 
centrifuge at 15000 rpm at 4˚C for 30 min. 
 The supernatant was then filtered through a 0.45 µm syringe filter and 5 mL of the crude 
protein was loaded onto His GraviTrap
TM
 hand columns. The column was equilibrated with 10 
mL of binding buffer before loading the crude protein 5 mL (as per given protocols), washed 
with 10 mL of binding buffer followed by 3 x 1 mL of elution buffer (500 mM imidazole, 20 
mM potassium phosphate, 500 mM NaCl, pH 7.4). One milliliter fractions were collected. The 
second elution was loaded onto a Superdex 200
TM
 (gel filtration) column. The column was 
equilibrated with one column volume of low ionic strength buffer (20 mM HEPES, 10 mM 
NaCl, pH 7.4) and two column volumes of high ionic strength buffer 20 mM HEPES, 50 mM 
NaCl, pH 7.4 (as per given protocol, GE healthcare). The protein was run with 20 mM HEPES, 
50 mM NaCl, pH 7.4 and collected 2 mL fractions at a flow rate of 1 mL/min.  
2.5 Protein Characterization 
2.5.1 Sodium dodecyl sulfate polyacrylamide gel electrophoresis (SDS-PAGE) 
 
Electrophoresis was performed in sodium dodecyl sulfate containing polyacrylamide gel 
with known molecular weight protein marker as a control with protein samples. A 10% resolving 
gel and 5% stacking gel were used to characterize protein. These gels were prepared according to 
the recipes in Table 2.1 and 2.2. Protein samples were mixed with loading dye (50 mM Tris (pH 
19 
 
6.8), 2% SDS, 0.2% bromophenol blue (tracking dye), 20% glycerol and 1% BME (reducing 
agent)) and heated for 10 mins at 100˚C. Running buffer (Tris-Glycine) was poured in to the 
chamber followed by protein sample loaded in to the wells.  
Table 2.1 SDS-PAGE Recipe- 15 mL Separating Gel 
 
Component 10 % Gel 
Water 7.1 mL 
1.5 M Tris (pH 8.8) 3.8 mL 
40 % Acrylamide mix 3.8 mL 
10% SDS 150 μL 
10% APS 150 μL 
TEMED 15 μL 
 
Table 2.2 SDS-PAGE Recipe- 5 mL Stacking Gel 
 
Component 5 % Gel 
Water 3.6 mL 
1 M Tris (pH 6.8) 0.63 mL 
40 % Acrylamide mix 0.63 mL 
10% SDS 50 μL 
10% APS 50 μL 
TEMED 5 μL 
 
 Samples were run at 140 volts. Once sample reached the bottom of the gel, staining was 
perfomed using Coommasie brilliant blue. Destaining was done using fast and slow destaning 
solution respectively (Fast destaning solution – 30% methanol and 10% acetic acid, slow 
destaning solution – 50% methanol and 10% acetic acid). Gels were dried using gel drying 
papers (VWR) or documented by photographs. 
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2.6 Site-directed mutagenesis 
 
 Protein sequences were obtained from GenBank. Primers were designed based on the DNA 
sequence of the wild type E. coli GUS through PrimerX (www.bioinformatics.org/primerx/) via 
Quick change site-directed mutagenesis kit (Stratgene). Other parameters such as GC% (40 – 
60%) and melting temperature (80˚C) were optimized. The plasmid DNA was isolated according 
to QIAprep spin miniprep kit manual protocols. 
 PCR reactions were performed in a final volume of 50 µL containing 5 µL of 10X PCR buffer 
(200 mM Tris–HCl, pH 8.8, 100 mM KCl, 100 mM (NH4)2SO4, 20 mM MgSO4, 1% Triton X-
100, 1.0 mg/mL BSA); 10 ng of plasmid DNA , 1-2 µL (15 pmole) of forward and reverse 
primers depending upon number of base pairs (Table 2.3); 1 µL dNTP (10 mM), 1 µL PFu turbo 
DNA polymerase (2.5 U). The final volume was adjusted to 50 uL with nuclease free water. 30 
µL of mineral oil was added in each of the Eppendorf tubes.  Amplifications were carried out in 
PTC
TM
 100 (Programmable thermal controller): initial denaturation at 95
o
C for 30 seconds; 
followed by 16 cycles of denaturation at 95
oC for 30 seconds, annealing at 55˚C for 1 min, and 
elongation at 68
o
C for 14 min. Amplified DNA samples were digested with 1 µL of dPN1 (10 U) 
and incubated for an hour at 37˚C with shaking. After digestion, transformation was performed 
as described previously. 
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Table 2.3 GUS primers for Polymerase chain reaction 
 
Mutant Primer Primer pair (5′ → 3′) % GC 
content  
Tm 
(°C) 
K568E Forward 
Reverse 
CGTTGGCGGTAACAAGGAAGGGATCTTCACTCG 
CGAGTGAAGATCCCTTCCTTGTTACCGCCAACG 
54.55 80.6 
K568Q Forward 
Reverse 
CGTTGGCGGTAACAAGCAAGGGATCTTCACTCG 
CGAGTGAAGATCCCTTGCTTGTTACCGCCAACG 
54.55 80.6 
R562E Forward 
Reverse 
CGACCTCGCAAGGCATATTGGAAGTTGGCGGTAACAAGAAAGG 
CCTTTCTTGTTACCGCCAACTTCCAATATGCCTTGCGAGGTCG 
51.16 79.7 
R562Q Forward 
Reverse 
GACCTCGCAAGGCATATTGCAAGTTGGCGGTAACAAGAAAG 
CTTTCTTGTTACCGCCAACTTGCAATATGCCTTGCGAGGTC 
48.78 80.1 
N566D Forward 
Reverse 
GCATATTGCGCGTTGGCGGTGATAAGAAAGGGATCTTCACTCG 
CGAGTGAAGATCCCTTTCTTATCACCGCCAACGCGCAATATGC 
51.16 79.7 
Y472E Forward 
Reverse 
GAACCGTTATTACGGATGGGAAGTCCAAAGCGGCGATTTGG 
CCAAATCGCCGCTTTGGACTTCCCATCCGTAATAACGGTTC 
51.22 78.9 
E504Q Forward 
Reverse 
GCCGATTATCATCACCCAATACGGCGTGGATACG 
CGTATCCACGCCGTATTGGGTGATGATAATCGGC 
52.94 80.4 
 
2.7 Enzyme Kinetics 
 
 Both native GUS and mutants were assayed using various substrates where initial velocity of 
the reaction was continuously monitored by increase in absorbance over time. The cuvettes 
containing the protein in buffer were incubated for 5 min and the reaction was initiated by 
addition of the substrate. All the measurements were done in duplicate. Kinetic parameters were 
determined by plotting rate vs substrate concentration using Prism software.  Rate of product 
formation was measured as change in absorbance per min following Beer’s law 
                   A = Ɛbc                                                                            (1) 
where A= absorbance, Ɛ= Molar extinction coefficient, b = Optical pathlength (1 cm) and c = 
concentration. 
 All the assay preparations were kept in an ice bath while performing the assays. The 
enzymatic release of p-nitrophenol, phenol and 4-methylumbelliferone from their glucuronides 
and glucuronamides conjugates were monitored at 405 nm, 265 nm and 365 nm respectively. 
The enzyme cleavage of p-nitrothiophenyl-β-D-glucuronide to generate p-nitrothiophenol was 
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monitored at 408 nm. The molar extinction coefficients of p-nitrophenol, phenol, p-
nitrothiophenol and 4-methylumbelliferone at pH 7.4 were 9000 M
-1
cm
-1
, 1100 M
-1
cm
-1
, 11000 
M
-1
cm
-1
 and 4000 M
-1
cm
-1
 respectively. Thiophenyl-β-D-glucuronide, glucuronic acid and p-
nitrophenyl-β-D-glucopyranoside were assayed as inhibitors against p-nitrophenyl-β-D-
glucuronide (PNPG). 
All substrate stocks were made in HEPES buffer (20 mM HEPES, 50 mM NaCl, pH 7.4) except 
phenyl-β-D-glucuronamide which was solubilized in 10% (v/v) DMSO, glucuronamide 
derivatized substrates were solubilized in a 55°C with the aid of water bath and these samples 
were kept at room temperature during enzymatic assays. The substrate concentration range 
typically varies from 0.01-1.0 mM range in an assay and all the assays were performed at room 
temperature (23°C ± 2). 
 
2.7.1 pH optimum study 
 Kinetic assay were also performed at different pH values, in duplicates to determine the pH 
optimum for GUS activity with both PNPG and PNPGun (concentration varied over 0.01 mM – 
3.0 mM). In order to cover a suitable pH range, reaction buffer was replaced with 0.1 M 
potassium acetate buffer (pH 4.0, 4.5, 5.0 and 5.5), 0.1M potassium phosphate buffer  (pH 6.0 
and 6.5), 0.1M HEPES buffer (pH 7.0, 7.5 and 8.0) and 0.1 M bicine buffer (pH 8.5 and 9.0). At 
each pH, release of p-nitrophenol was measured at 405 nm. The assays were performed using the 
same procedure as described above. 
 
2.7.2 Data Processing 
 Obtained slope over time were input into the Graphpad prism (Version 3.0) software and 
fitted by non-linear regression to the Michaelis-Menten equation. The software output gives Vmax 
and Km. The initial velocity data were fitted in the following equations  
 o   
      
    
                                                                                        (2) 
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 o   
      
                 
                                                                           (3) 
 o   
      
                        
                                                                    (4) 
 
where V0 - initial velocity, Vmax - maximum velocity, [S]- substrate concentration, and Km- 
Michaelis-Menten constant for the substrate. Ki is the inhibition constant. Equation 3 and 4 
represents Competitive and non-competitive inhibition models respectively. 
 
2.7.3 Inhibition studies of GUS with p-nitrophenyl-β-D-Glucopyranoside (PNPGluc), 
Glucuronic acid and Thiophenyl-β-D-Glucuronide (PGS) 
 
 Assays were conducted as described above with the addition of potential inhibitors (PNPGluc 
or Glucuronic acid or PGS) to the reaction mixture (protein and reaction buffer) and incubated 
for 5 mins prior to initiation with PNPG. Three different concentrations of PNPGluc and 
Glucuronic acid were used (2 mM, 4 mM and 6 mM) while varying PNPG concentrations (0.01- 
1 mM range). In case of PGS, concentrations were (0.5 mM, 1 mM and 1.5 mM) with varying 
PNPG concentrations (0.01- 1 mM range). The inhibition constants for all the potential inhibitors 
were calculated using Sigma plot software which is discussed later in this thesis. 
 
2.7.4 Fluorescence assay 
 
 The fluorescence assays were conducted with 4-methylumbelliferone as the flurophore with 
an excitation wavelength of 365 nm for which emissions were monitored at 445 nm. A 4-
methylumbelliferone (MU) standard curve was measured to determine the rate of formation of 
MU- derivatized GUS substrates (Fig 2.1). Fluorescence assay were measured in triplicates. 
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Figure 2.1 Standard curve of 4-methylumbelliferone (MU) 
 
The concentration of MU produced in the assay was determined by the least squares regression 
equation for the line generated by the standard 4MU calibration. The equation for a line is y = 
mx + c, where y is the instrument reading-relative fluorescence units (RFU), x is the sample 
concentration (µM), m is the slope of the line, and c is the y-intercept
70
. 
 
2.8 Circular Dichroism Studies 
 
 CD studies on wild type and GUS mutant samples were done using 20 mM potassium 
phosphates buffer pH 7.4. As such protein samples were dialyzed using Vivaspin 500 (MWCO 
30000 PES, 30 kDa cut-off polythersulfone membrane concentration device) protein centrifuge 
columns at 6000 rpm for 10 min at 4˚C using Beckman Microfuge 18 Microcentrifuge. CD 
measurements were performed under Far-UV region at a temperature of 4°C. CSA 4 mM ((1S)-
(+)-10-camphorsulfonic acid) was used as a standard to calibrate the instrument at 290.5 nm. 
Five scans were conducted and averaged for each sample from  190-260 nm at 0.5 nm interval 
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using a 6 nm bandwidth with a rate of 5 nm per min. Samples were at a concentration of 1 
mg/ml, degassed prior to the experiment and spectra were recorded for different mutants at 4˚C. 
 The optical path was 0.1 mm. Each spectrum was generated from the average of 5 scans. CD 
spectra were corrected with respect to the baseline and buffer employed for the measurement. 
Molar elipticity was calculated based upon the concentration of each sample using formula:  
   =
  M  100
C  
                                                        (5) 
 here [ ] is molar ellipticity, expressed in milidegrees cm2 decimole-1,   is ellipticity given by 
the instrument (milidegrees), C is the concentration (g/mL), and l is the optical length (cm). 
CDNN deconvolution program
69
 was used in determining secondary structure details. 
 
2.9 Isothermal Titration Calorimetry 
 
GUS was dialyzed in 20 mM HEPES, 50 mM NaCl, pH 7.4 using 30 kDa cut-off 
polythersulfone membrane concentration device (Vivaspin) to a final concentration range of 50 -
300 µM. Samples were degassed for a period of an hour before starting the experiments. A stable 
baseline was achieved prior to the start of the ligand injections. Experiments were done at 25˚C 
and samples were stirred at rate of 300 rpm. Equilibration time between the injections was 150-
200 sec. The data obtained was corrected for dilution heat by subtracting excess heat at high 
molar ratio of ligand to protein. Nano Analyze software provided by TA instruments was used to 
determine the enthalpy (∆H), binding affinity (K) and entropy (∆S) using independent model 
included in the software. Gibbs free energy (∆G), Kd (dissociation constant) and heat for 
independent model (1:1) considering one ligand per active site was determined using equation 6, 
7, 8 and 9. 
                                                                     (6) 
                                                                    (7) 
                                                                      (8) 
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                                                                   (9) 
                                                                                                                                 (10) 
Combining equation 9 and 10, above gives 
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Total heat generated from the solution in cell V0 is measured as at fraction saturation   is 
                                                                                                                                 (12) 
By solving 11 and substituting in 12, gives  
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Where L AND [L] are bulk and free ligand concentration (mM) 
 [P] is the protein concentration in the calorimetric cell (μM) 
 Q is the heat released/absorbed (kJ/mol), n is the stoichiometry 
 K is the affinity constant (M
-1
) 
Vo is the cell volume (mL) and ∆H is the enthalpy (kJ/mol). 
n is number of binding sites 
  = fraction of sites occupied by ligand L  
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3 RESULTS AND DISCUSSION 
3.1 Protein purification 
 The E. coli GUS-containing over-expression construct with N-terminal Histidine tag (His-tag) 
was successfully cloned and eexpressed previously. Full characterization of GUS and its mutants 
with a variety of substrates requires a purification method which produces large quantities of 
highly pure protein.  As such, we optimized the purification to produce large quantities of 
purified protein to homogeneity for kinetic assays and crystallization trials. Purification of 
protein was carried out using a His-Gravi Trap hand column (gravity based) followed by size 
exclusion chromatography as reported
51
. SDS-PAGE was run to identify the purity of GUS along 
with reference to a known molecular weight marker. (Fig 3.1).The histidine tagged protein binds 
with nickel ions on the column. The column was then washed with binding buffer to discard the 
other untagged protein leaving the His-tagged protein on the column. 
 
  
 
 
 
 
 
 
Figure 3.1 SDS-PAGE of E. coli GUS - The gel shows the purification of E. coli GUS from His-Gravi Trap 
and gel filtration column.  Lanes 1: (Flow through,FT) Crude protein load onto column, Lanes 2:  (Wash,W) 
Column wash, Lanes 3: I Elution (IE), Lanes 4: -II Elution (IIE), Lanes 5: III Elution (IIIE), Lanes 6-8:  Fractions 
from gel filtration column (GI, GII, GIII), Lanes 9: SDS Mol. Wt. Marker (MW). 
 FT     W      IE       IIE     IIIE    GI      GII     GIII   MW 
kDa  
66  
 
45 
36
  45 
29 
24 
20 
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Figure 3.2 Size exclusion chromatogram of Wt GUS 
 
 The His-tag protein was eluted with elution buffer containing higher concentration of 
imidazole. As a result histidine analog imidazole competes for the binding with nickel ion on the 
column and the protein is eluted out with high concentration of imidazole. Eluted GUS was 
further purified by size exclusion/ gel fitration column.  The larger molecules are excluded faster 
from the gel due to less volume to diffuse through the gel. While smaller molecules diffuse into 
the gel and migrates slowly through the column giving the pure fraction of protein. The 
chromatogram showing single peak represent pure fraction of protein with no contamination (Fig 
3.2). The monomer mass of GUS is 68 kDa, which appears slightly above the 66 kDa sample of 
the molecular weight marker. 
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3.2 Kinetic investigation of Wt GUS Substrate specificity 
 
GUS is a type 2 glycoside hydrolase that catalyzes the cleavage of β-D-glucuronides43. 
The enzyme is highly specific for the glucuronide moiety of the substrate. Given that glucosides 
are not substrates for the enzyme, the glucuronide 6-carboxylate group, with its putative negative 
charge, must be important for recognition of the substrate. Docking studies conducted through 
GOLD software with glucuronic acid showed C6 carboxylate group is important in making 
specific interaction with the active site residues
51
. Our docking studies showed active site 
residues Y472, K568, R562, D163 and N566 forms hydrogen bond with C-6 carboxylate group   
(as shown in Fig 1.7). Negatively charged C6 carboxylate group of glucuronide moeity was 
substituted to its neutral carboxamide, which was studied with different aglycone groups, to 
determine substrate selectivity of GUS. As discussed above, the carboxamide derivative 
BA3GNamide is not a substrate for GUS from a previous study. In order to make a poor 
substrate for native GUS it was tested out with different aglycone groups such as p-nitrophenol, 
phenol and 4-methylumbelliferone which were studied kinetically with glucuronide and 
glucuronamide derivatives. Previously it was found that any aglycone moiety can be attached to 
the glucuronide moiety. As a test of this, different size aglycone moieties were used.  Initial 
velocities for the reactions were determined by straight line slope of graph, typically from the 
first 1 min of the reaction. The concentration of the enzyme was much smaller compared to the 
substrate concentration in all the assays. Vmax and Km values were obtained initially from the 
Prism software. The kcat is the substrate turnover rate by the enzyme per unit time while kcat/Km 
value determines enzyme efficiency for the substrate. 
3.2.1 p-Nitrophenyl derivatives 
3.2.1.1 p-Nitrophenyl-β-D-glucuronide (PNPG) 
 PNPG is a well-known substrate for Wild-type (Wt) GUS and is a widely used reporter 
system for gene expression
45
. When PNPG is hydrolyzed by GUS, p-nitrophenol (pKa = 7.1 and 
its molar extinction coefficient  (Ɛ) is 9000 M-1cm-1) 71,72 is formed as  a yellow chromogenic 
product. As such GUS activity was continuously monitored spectrophotometrically at 405 nm. 
The specificity constant for PNPG is in the order of 10
3 
mM
-1
cm
-1
, binding is 0.12 mM and the 
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turnover rate is 101 s
-1
. One of the previous studies on Wt GUS showed 10 fold higher values for 
specificity while other has similar values with PNPG (Table 3.1 and Fig 3.3) 
(a) 
 
(b) 
        
Figure 3.3 Hydrolysis of PNPG catalyzed by Wt GUS  
(a) Reaction catalyzed by GUS using PNPG as substrate (b) Michaelis-Menten curve of Wt GUS. Measurements for 
each point were done in duplicate. Error bars are obscured by symbol. 
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Table 3.1 Kinetic parameters of Wt GUS with its natural substrate PNPG. 
Substrate Enzy e   ( M) kc t (s
-1
) kc t/  ( M
-1
s
-1
) 
PNPG
#
 E. coli GUS 0.12 ± 0.01 101 ± 2    840 ± 73 
PNPG
48
 Thermotoga 
maritima GUS 
0.15 ± 0.01 68 ± 2 453 ± 33 
PNPG
73
 E. coli GUS 0.20 ± 0.01 68 ± 6 340 ± 20 
PNPG
74
 E. coli GUS 0.26 ± 0.01 109 ± 42 410 ± 20 
PNPG
75
 E. coli GUS 0.24 ± 0.08    200 ± 6   833 ± 278 
PNPG
76
 E. coli GUS 0.10 ± 0.01 878 ± 31 8600 ± 896 
        # - Bold indicates results from this study 
 
3.2.1.2 p-Nitrophenyl-β-D-glucuronamide (PNPGun) 
 
 PNPGun was examined as a substrate to see the effect of carboxamide versus carboxyl group 
at C-6 position of PNPG. The glucuronamide that is not a substrate for GUS is BA3GNamide
46
. 
PNPGun showed 20 fold lower turnover rate and 10 fold less substrate specificity compared to 
PNPG (Table 3.2 and Fig 3.4). Interestingly PNPGun (0.06 mM) binds with twice the affinity of 
PNPG (0.12 mM). The result indicates while the amide derivative turned over at a significantly 
slower rate, it bound more tightly. The reason for better binding could be the inductive effect of 
nitro group which was not seen in phenyl and MU derivatives as discussed later in this thesis. 
This result would be good from a substrate point of view since there was a slower turnover rate 
for Wt GUS. The ideal substrate should show no turnover for the native enzyme which will 
ultimately aid in prevention of unwanted activation of prodrug. 
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(a) 
 
(b)  
         
Figure 3.4 Hydrolysis of PNPGun catalyzed by Wt GUS.  
(a) Reaction catalyzed by GUS using PNPGun as substrate (b) Michaelis-Menten curve of Wt GUS. Measurements 
for each point were done in duplicate. Error bars are obscured by symbol. 
3.2.1.3 p-Nitrothiophenyl-β-D-glucuronide (PNSPG) 
 
  S-Glucuronide derivatives such as p-nitrothiophenyl-β-D-glucuronide (PNSPG) were also 
studied to determine the effect of changing substituents within the leaving group. The leaving 
group in this case would be p-nitrothiophenol (PNTP) (pKa = 4.5 )
77
, which was monitored at 
408 nm, has molar absorptivity (Ɛ) 11000 M-1cm-1. PNSPG was found to be a poor substrate for 
GUS with a turnover rate of 1000 fold less than PNPG (Table 3.2 and Fig 3.5). A plausible 
reason could be that sulfur is less electronegative than oxygen, so it does not get protonated as 
fast by the general acid/ base E413 residue. As well, the size and the related conformation of 
PNSPG could be a reason, as atomic size of sulfur is bigger than oxygen. The results are in good 
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agreement with literature reports
78
 which also showed 1000 fold decrease in turnover rate with S-
glycosides (sulfur analogues) versus O-glycosides, although their Km values are not affected 
79
. 
(a)
 
(b) 
         
 
Figure 3.5 Hydrolysis of PNSPG catalyzed by Wt GUS.  
(a) Reaction catalyzed by GUS using PNSPG as substrate (b) Michaelis-Menten curve of Wt GUS. Measurements 
for each point were done in duplicate. Error bars are obscured by symbol. 
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Table 3.2 Kinetic parameters of p-nitrophenyl derivatives. 
Substrate Km (mM) kc t (s
-1
) kc t/  ( M
-1
s
-
1
) 
PNPG 0.12 ± 0.01 101 ± 2 840 ± 73 
PNPGun 0.067 ± 0.003 5.1 ± 0.1 86 ± 5 
PNSPG 0.23 ± 0.02 (12.9 ± 0.4) x 10
-2
 (55 ± 5) x 10
-2
 
                        # - Bold indicates results from this study 
 
 
3.2.1.4 Inhibition of Wt GUS activity by p-nitrophenyl-β-D-glucopyranoside (PNPGlu) 
 p-Nitrophenyl-β-D-glucopyranoside (PNPGlu) was also studied as a substrate analogue. It 
differs from PNPG at C6 position by the absence of carbonyl oxygen. It showed trace activity in 
the presence of significantly higher concentrations of Wt GUS. As such  PNPGlu is not 
determined to be a substrate for Wt GUS which is in agreement with previous reports in the 
literature
44
. Given the similarity and trace activity of PNPGlu with PNPG, it seems likely that it 
would be capable of fitting inside the active site. Consequently, PNPGlu was tested as an 
inhibitor for GUS activity with PNPG. The inhibition constant (Ki) is the concentration of 
inhibitor required to reduce the rate to half of the uninhibited value. The higher the Ki value the 
weaker the inhibitor binds to the enzyme and vice versa.  The Ki value represents a similar 
concept to the Km value which is a function of ligand binding. The Ki value was measured by 
using Sigmaplot software.  Initial velocities were obtained in duplicates for each of the 
concentration of PNPGlu against PNPG. The obtained kinetic data was fitted to both competitive 
and non-competitive equations. The resulting trends shown in Fig 3.6, fit well to that of non-
competitive inhibition model (based on value of R
2
 = 0.99) and showed weak inhibition with Ki = 
5.01 mM. Significant less robust fits were obtained when the kinetic data was fitted to the 
equations for competitive inhibitors (R
2
 = 0.93). The results indicate that PNPGlu binds 
significantly weaker than all other substrates examined in this study. 
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Figure 3.6 Dixon plot of inverse initial velocity (1/µM/min) vs concentration of PNPGlu at 
various concentration of PNPG (range 0.01-1.0 mM).  
 
3.2.2 Phenyl derivatives 
3.2.2.1 Phenyl-β-D-Glucuronide (PG) 
 Phenyl derivatives of glucuronide and glucuronamide were also studied for substrate turnover 
rate and binding to examine for the un-substituted phenyl group. Kinetic results from PG showed 
that the turnover rate was 5 fold less and binding was 2 fold less than for PNPG (kcat = 22 per sec 
and Km = 0.23 mM) (Table 3.3 and Fig 3.7). PNPG acts as a better substrate than PG due to p-
nitrophenol (PNP) being a better leaving group (pKa = 7.1) compared to the phenol group (pKa = 
9.9). The inductive effect of the nitro group in PNP plays a significant role in the level of 
activity
78
.  
(a) 
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(b) 
       
Figure 3.7 Hydrolysis of PG catalyzed by Wt GUS.  
(a) Reaction catalyzed by GUS using PG as substrate (b) Michaelis-Menten curve of Wt GUS. Measurements for 
each point were done in duplicate. Error bars are obscured by symbol. 
 
 
3.2.2.2 Phenyl-β-D-Glucuronamide (PGun) 
 
The carboxamide analogue of the phenyl derivative namely PGun was also tested for 
substrate activity. Kinetic analysis of PGun exhibited 15 fold less activity than PG (kcat = 1.5 s
-1
) 
with two fold weaker binding (Km = 0.41 mM) (Table 3.3 and Fig 3.8). The unsubstituted phenol 
group is not a good leaving group and due to this PGun showed much lower activity compared to 
p-nitrophenol analogue and this may explain that the nitro group has its importance in substrate 
binding. Due to solubility issues with PGun in HEPES buffer, DMSO was added to reach 
suitable phenyl-β-D-glucuronamide solubility.  In the kinetic assay with PGun substrate, the 
DMSO concentration was maintained at 1% for each substrate concentration.  
A separate experiment was conducted to investigate the effect of DMSO on substrate binding. 
The enzyme was exposed to different concentrations of DMSO (1%, 5% and 10%) in final 1 mL 
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assay using PNPG as substrate. The Km values were found to be within the error limit when 
using 1% DMSO in the assay, while higher DMSO concentrations (5% and 10%) substrate 
binding was negatively affected (Table 3.4).  
Acetonitrile was also examined as a solubilizing agent for PGun with the GUS kinetic 
assay. However, at a 1% concentration, acetonitrile was found to increase the Km value by 50% 
i.e. reduced the overall binding by half to its original value. Previous studies have shown the 
presence of  either DMSO or acetonitrile negatively impact substrate binding
80
. 
 
Table 3.3 Kinetic parameters of Phenyl derivatives. 
Substrate Km (mM) kc t (s
-1
) kc t/  ( M
-1
s
-1
) 
PG 0.20 ± 0.02 22 ± 1 110 ± 11 
PGun 0.41 ± 0.06 1.5 ± 0.1 3.6 ± 0.6 
 
Table 3.4 Kinetic parameters of GUS with PNPG as substarte at various concentrations of DMSO. 
DMSO Conc.    ( M) kc t (s
-1
) kc t/  ( M
-1
s
-1
) 
0% 0.13 ± 0.01 101 ± 2 777 ± 62 
1% 0.14 ± 0.01 95 ± 2 679 ± 51 
5% 0.15 ± 0.01 98 ± 3 653 ± 48 
10% 0.19 ± 0.01 99 ± 3 521 ± 32 
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(a) 
 
(b) 
         
Figure 3.8 Hydrolysis of PGun catalyzed by Wt GUS.  
(a) Reaction catalyzed by GUS using PGun as substrate (b) Michaelis-Menten curve of Wt GUS. Measurements for 
each point were done in duplicate. Error bars are obscured by symbol. 
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3.2.2.3 Phenyl-1-thio-β-D-Glucuronide (PGS) 
 
 
 
The S Glucuronide derivative PGS was studied with Wt GUS to examine the 
unsubstituted phenyl group. Ultimately kinetic studies revealed that PGS is neither a substrate 
nor an inhibitor for Wt GUS. The results are in agreement with the previous studies
78
. One study 
explained that thiols are not good substrates in undergoing general-acid-catalyzed nucleophilic 
substitution reactions at acetal centers
77, 81
. In case of p-nitrothiophenyl-β-D-Glucuronide 
(PNSPG), the nitro group of phenyl ring increases the catalytic activity compared to PGS, due to 
a beneficial inductive effect. Size and conformation of the PNSPG may play important role, 
which may partly explain why PNSPG is hydrolyzed by Wt GUS while the glucuronide of 
thiophenol (pKa = 6.4)
77
 is not
78
. Previous studies revealed that the rate of hydrolysis is slowest 
for the unsubstituted phenyl  group and binds weakly 
45
. 
 
3.2.3 4-methylumbelliferyl (MU) derivatives  
3.2.3.1 4-methylumbelliferyl-β-D-Glucuronide (MUG) 
 
In order to further probe the effects of the leaving group on Wt GUS activity, MUG was 
employed as a substrate. Additionally, the amide-derivative, namely MUGun, was also 
investigated for Wt GUS activity to evaluate the effects of changing the functional group at the 
C6 position. The cleavage product, 4-methylumbelliferone, is a fluorescencent compound, 
formed as a product of enzymatic catalysis of substrate MUG
82
 which allowed for the kinetic 
assay to be evaluated using UV spectroscopy and spectrofluorometrically (Table 3.5 and Fig 
3.9). Experimentally results showed that MUG turnover rate (kcat) is 43 s
-1
 and Km = 0.11 mM, 
40 
 
was the same as PNPG. Two separate studies, one using human GUS and the other using E. coli 
GUS used MUG as substrate and showed specificity at the same scale (~100 mM
-1
S
-1
). Using 
different leaving groups like p-nitrophenol, phenol, 4-methylumbelliferone suggests that the nitro 
group has a significant effect on substrate catalysis rate.  
 
(a) 
 
(b) 
        
 
Figure 3.9 Hydrolysis of MUG catalyzed by Wt GUS.  
(a) Reaction catalyzed by GUS using MUG as substrate (b) Michaelis-Menten curve of Wt GUS. Measurements for 
each point were done in duplicate. Error bars are obscured by symbol. 
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3.2.3.2 4-methylumbelliferyl-β-D-Glucuronamide (MUGun) 
 
  Kinetic assays performed with the amide-derivative, namely MUGun, revealed two fold 
weaker binding (Km = 0.20 mM) than MUG while the turnover rate was 9 fold slower than MUG 
(kcat = 5 s
-1
). Kinetic parameters were determined on both by UV spectroscopy and 
spectrofluorometrically (Table 3.5 and Fig 3.10). The slower turnover and weaker binding 
observed for the MUGun is consistent with the kinetic findings for the PG/PGun substrate pair.  
Interestingly, while a similar reduction in the turnover rate was observed for the PNPG/PNPGun 
pair, the binding in that case was found to be tighter for the amide analogue. 
(a) 
 
(b) 
 
        
Figure 3.10 Hydrolysis of MUGun catalyzed by Wt GUS.  
(a) Reaction catalyzed by GUS using MUGun as substrate (b) Michaelis-Menten curve of Wt GUS. Measurements 
for each point were done in duplicate. Error bars are obscured by symbol. 
R
a
te
 o
f 
fo
rm
a
ti
o
n
  
42 
 
 
 
Table 3.5 Kinetic parameters for MUG and MUGun. (F)-spectrofluorometrically, (UV)-ultravoilet. 
Substrate Km (mM) kcat (s
-1
) kcat/Km (mM
-1
s
-1
) 
MUG (UV) 0.11 ± 0.01 47 ± 1 390 ± 44 
MUG
47
 2.76 276 100 
MUG
51
 n/a n/a 134 ± 12 
MUGun (UV) 0.20 ± 0.06 5 ± 1 25 ± 5 
MUG (F) 0.11 ± 0.02 43 ± 3 391± 77 
MUGun (F) 0.25 ± 0.1 6 ± 1 25 ± 10 
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Table 3.6 Summary of kinetic parameters of various substrates used against Wt GUS  
 
Substrate Km (mM) kcat (s
-1
) kcat/Km (mM
-1
s
-1
) 
PNPG 0.12 ± 0.01 101 ± 2 840 ± 73 
PNPGun 0.067 ± 0.003 5.1 ± 0.1 86 ± 5 
PNSPG 0.23 ± 0.02 (12.9 ± 0.4) x 10
-2
 (55 ± 5) x 10
-2
 
PGS n/a n/a n/a 
PG 0.20 ± 0.02 22 ± 1 110 ± 11 
PGun 0.41 ± 0.06 1.5 ± 0.1 3.6 ± 0.6 
MUG 0.11 ± 0.01 47 ± 1 390 ± 44 
MUGun 0.20 ± 0.06 5 ± 1 25 ± 5 
MUG (F) 0.11 ± 0.02 43 ± 3 391± 77 
MUGun (F) 0.25 ± 0.1 6 ± 1 25 ± 10 
PNPGluc trace activity, Ki = 5 mM 
                         *n/a- PGS was neither a substrate nor an inhibitor 
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3.3 Kinetic Investigation of GUS Mutants 
 
Site directed mutagenesis was performed on residues which were believed to be 
important for binding substrate within the active site.  As crystallographic evidence for substrate 
binding is not available, docking studies were used to initially identify which residues could be 
potentially important targets. In addition to elucidating putative roles for substrate binding, the 
mutagenic GUS study was also aimed at improving the catalytic activity of the PNPGun 
substrate in the context of ADEPT specificity. As a result only mutated analogs of GUS will 
catalyze the reaction for amide-derivatized substrate not the native GUS. In this case PNPGun 
was used initially to optimize the mutations for GUS. 
 The enzymatic catalysis takes place through residues E504 and E413, which are within 3 Å of 
the glycosidic bond oxygen
44
. E504 acts as a nucleophile, while E413 acts as general acid/base. 
The N terminal 180 residues represents the sugar binding domain of family 2 glycosyl 
hydrolases
66
, whereas the C terminal domain (residues 274-603) forms an (β/α)8 barrel and 
contains the active-site residues
50, 66
. Residues Y472, E504, R562, N566 and K568 are present on 
C terminal domain making important interactions with the substrate as per docking studies (Fig 
1.7) and they all line the substrate binding pocket
44, 51, 67
.  
Preliminary modeling studies showed that both PNPG and PNPGun interact with the 
active site residues in a similar manner (Fig 3.11). Interestingly, kinetic experiments on Wt GUS 
revealed PNPGun has a significantly reduced turnover rate although the binding was twice as 
strong. In order to recover the activity for PNPGun which would make it a better substrate for 
use in ADEPT, point mutations were made to the residues proposed to make important 
interactions with the derivatized C6 position. The point mutations were chosen specifically to 
also probe which residues were important for native substrate binding. 
From our hypothesis, it was also suggested that the positively-charged residues lysine 
568 and arginine 562 interact with the negatively charged C6 carboxylate of PNPG when bound 
to the enzyme. To test this hypothesis, site-directed mutants were generated, and activity of these 
mutants was compared to the wild-type enzyme using a glucuronide derivative (PNPG) and its 
neutral glucuronamide analouge (PNPGun). 
45 
 
 
 
Figure 3.11 PNPG and PNPGun are modeled in the active site of E. coli GUS (PDB: 3K4D). 
PNPG (green) and PNPGun (yellow) 
 
 
 To examine the hypothesis, positively charged residues were mutated to negatively charged or 
neutral residues to investigate the ionic interactions. The residues forming the binding pocket as 
per docking studies were mutated. The resultant mutants were aimed considering the C6 
carboxylate interaction with the native GUS residues. Successful mutations were made to 
Y472E, E504Q, R562E, N566D, K568E and K568Q. The mutants were purified with minimal 
impurities which were verified by SDS-PAGE (Fig 3.12). 
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                    1          2              3          4           5             6             7             8 
                   
Figure 3.12 SDS-PAGE of GUS mutants.  
From left, Lane 1: SDS Marker. Lane 2: R562E. Lane 3: R562Q. Lane 4: K568E. Lane 5: K568Q. Lane 6: Y472E. 
Lane 7: N566D. Lane 8: E504Q.  
 
 
3.3.1 E504Q 
E504 is an important residue in active site for enzymatic catalysis, acting as catalytic 
nucleophile. It attacks at the anomeric carbon (C1) of the glucuronic acid moiety which leads to 
the formation of glycosyl enzyme intermediate (Scheme 2). The docking studies revealed E504 
forms hydrogen bonds with the C2 hydroxyl group. Glutamic acid at this position was mutated to 
glutamine, which removed the charge and kept the size constant. This mutation should allow for 
the stabilizing hydrogen bond to form with the substrate while eliminating the role as 
nucleophile. As such, it was expected that this mutant would not exhibit significant activity.  
Indeed E504Q mutation results in marginal 0.01 % activity (Table 3.7 and Fig 3.13), which is 
consistent from previous results (Table 3.9). As well no activity was observed for PNPGun 
(Table 3.8), which further supports the fundamental role played by E504 in enzymatic catalysis.  
kDa  
66  
 
45 
36
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Figure 3.13 Hydrolysis of PNPG catalyzed by GUS E504Q.  
(A) Michaelis-Menten curve comparison of Wt GUS and GUS E504Q using PNPG as substrate. (B) Michaelis-
Menten curve of GUS E504Q. Measurements for each point were done in duplicate. Error bars are obscured by 
symbol.  
 
3.3.2 R562Q/ R562E 
 
R562 is believed to be important for substrate binding as docking studies suggests a 
strong interaction with the C6 carboxyl group of PNPG. Arginine is presumed to have a 
stabilizing effect through ionic interaction with the negatively charged C6 carboxylate. Mutating 
arginine to the neutral charged glutamine (R562Q) greatly reduced the activity to 1.5 % of the 
wild type activity for both PNPG (Table 3.7 and Fig 3.14) and PNPGun (Table 3.8 and Fig 
3.15) while substrate binding (Km) was not effected compared to the wild type.  
R562 was also mutated to glutamate (R562E) to introduce the negative charge which would 
hinder the formation of hydrogen bonding to C6 carboxylate of the PNPG. However kinetic 
results showed similar binding to that of wild type GUS with significant reduced activity 
(0.03%) (Table 3.7 and Fig 3.16). This would suggest in this case that ionic contributions are not 
essential for binding per se, but are required for functional binding.  In the context of the 
previous experiment, the R562E mutation was not expected to have as significant an impact on 
the activity with the neutral C6 amide of PNPGun. However, the kinetic analysis showed trace 
activity for R562E with PNPGun which could not be quantified (Table 3.8).  Another 
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explanation for decreased activity of the R562E mutant could be difference in size between the 
residues. A smaller residue in this position could interrupt the steric fit for productive substrate 
binding.  Lastly, the anticipated effect of introducing a negative charge at R562 may have been 
partially offset by the presence of an adjacent positively charged residue, namely K568. 
 
Figure 3.14 Hydrolysis of PNPG catalyzed by R562Q.  
Michaelis-Menten curve of R562Q. Measurements for each point were done in duplicate. Error bars are obscured by 
symbol. 
 
          
Figure 3.15 Hydrolysis of PNPGun catalyzed by R562Q.  
Michaelis-Menten curve of R562Q. Measurements for each point were done in duplicate. Error bars are obscured by 
symbol. 
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Figure 3.16 Hydrolysis of PNPG catalyzed by R562E.  
Michaelis-Menten curve of R562E. Measurements for each point were done in duplicate. Error bars are obscured by 
symbol.  
 
3.3.3 K568Q/K568E 
 
In addition to R562, K568 also provides a positively charged hydrogen bonding group for 
interaction with the C6 carboxylate of PNPG. Within this region, the active site can be made less 
positively charged by replacing the lysine with a neutral glutamine residue (K568Q) or with a 
negatively charged glutamate (K568E).  Both of these mutants were produced, purified, and 
characterized through kinetics to establish their effect on PNPG and PNPGun activity. 
The kinetic data shows that mutation of K568 to either glutamine or glutamate results in 
an enzyme with complete loss of activity for both PNPG and PNPGun . The results indicate that 
this residue is vitally important for catalytic activity. These deleterious  mutations are in line with 
previous conducted studies
44
 (Table 3.9). Although the kinetic data shows K568 is vital for 
assisting substrate turnover; it is unclear as to whether the substrate is binding in the active site 
as K568 was found, through modelling studies, to be a potentially important residue for 
stabilizing binding of the functional group at the C6 position of the substrate. In order to obtain 
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such information, Isothermal titration calorimetry (ITC) was performed on this GUS mutant and 
will be discussed below. 
 
3.3.4 Y472E 
 
Tyrosine 472 was found, through modelling studies to be a potentially important residue 
for stabilizing binding of the functional group at the C6 position of the substrate. Y472 is one of 
three tyrosine residues (Y469 and Y468) which are part of an adjacent loop postulated to play a 
role in binding the sugar portion of the substrate as well as stabilizing the aglycone moiety 
51, 61
. 
It was anticipated that the Y472E mutant would disrupt hydrogen bond formation with the C6 
carboxylate of PNPG due to charge-charge repulsion. As with previous mutants in this region, 
interaction of a negatively charged proton acceptor residue with the amide functionality of 
PNPGun was expected to enhance binding and potentially increase substrate reactivity. The 
kinetic data revealed the Y472E mutation results in weaker binding and decreased PNPG 
activity. The results suggests that the tyrosine residue is responsible for the proper steric fit of the 
substrate in the active site (Table 3.7 and Fig 3.17) and PNPGun activity was not observed 
(Table 3.8). The previous studies on GUS obtained from different organisms showed reduced 
activity when mutating these tyrosines (Table 3.9). In case of Scutellaria baicalensis GUS Y281A 
mutation reduced the activity to 0.1%, while Y504A mutation in Human GUS showed 0.07 % activity.  
Similarly in Acidobacterium capsulatum GUS, Y334F and Y243A mutations showed activity by less 
than 1% (Table 3.9). 
51 
 
       
Figure 3.17 Hydrolysis of PNPG catalyzed by Y472E.  
Michaelis-Menten curve of Y472E. Measurements for each point were done in duplicate. Error bars are obscured by 
symbol. 
 
3.3.5 N566D 
Modelling studies on glucuronic acid, PNPG, and PNPGun all suggest hydrogen bonding 
interactions are in operation between N566 and the functional groups (carboxylate and amide) at 
the C6 position. As with previous mutants, N566D was anticipated to experience repulsion with 
the carboxylate at the C6 position of PNPG while participating in stabilizing ionic interaction 
with C6 amide group of the PNPGun. While this mutation results in loss of activity of the 
enzyme and 10 fold decrease in binding with PNPG (Table 3.7 and Fig 3.18), no activity was 
seen with PNPGun (Table 3.8). A study using E. coli GUS, where N566 was mutated to serine 
(N566S), resulted in a  decrease of activity to 4%
74
 (Table 3.9) while in this study N566D results 
in marginal activity (0.04 %).  The plausible reason for N566D mutation is that it would remove 
the potential for the residue to act as a hydrogen bond donor, which is likely the cause of reduced 
binding and inability to help stabilize the substrate in a productive binding mode. In the case of 
PNPGun, it seems that the ionic portion of the interaction is not as important as there being the 
correct hydrogen bond donor present on the residue. The obtained result suggests importance of 
this residue at its position. 
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Figure 3.18 Hydrolysis of PNPG catalyzed by N566D.  
Michaelis-Menten curve of N566D. Measurements for each point were done in duplicate. Error bars are obscured by 
symbol. 
 
 
Table 3.7 Kinetic parameters of GUS mutants towards PNPG.  
Enzyme Substrate Km (mM) kcat (s
-1
) kcat/Km (mM
-1
s
-1
) % Activity 
Wt GUS PNPG 0.12 ± 0.01 101 ± 2 840 ± 73 100 
N566D PNPG 1.2 ±  0.2 (40 ± 3) x 10
-3
 (34 ± 6) x 10
-3
 0.04 
Y472E PNPG 3.2  ± 0.9 (10  ± 1) x 10
-2
 (3  ± 1) x 10
-2
 0.1 
E504Q PNPG 0.11 ± 0.01 (14 ± 1 ) x 10
-3
 0.11 ± 0.01 0.01 
R562E PNPG 0.10  ± 0.01 (35  ± 1) x 10
-3
 (36  ± 2) x 10
-2
 0.03 
R562Q PNPG 0.09 ± 0.01 1.66 ± 0.01 18 ± 1 2 
K568Q PNPG No activity n/a 
K568E PNPG No activity n/a 
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Table 3.8 Kinetic parameters of GUS mutants towards PNPGun. 
 
Enzyme Substrate Km (mM) kcat (s
-1
) kcat/Km  
(mM
-1
s
-1
) 
% Activity 
Wt GUS PNPGun 0.067 ± 0.003 5.1 ± 0.1 86 ± 5 100 
K568Q PNPGun No activity n/a 
K568E PNPGun No activity n/a 
E504Q PNPGun No activity n/a 
R562Q PNPGun 0.07 ± 0.01 (68 ± 1) x 10
-3
 (97 ± 5) x 10
-2
 1 
R562E PNPGun No activity n/a 
Y472E PNPGun No activity n/a 
N566D PNPGun No activity n/a 
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Table 3.9 Comparison of the percent activity of GUS mutants with previous published results 
 
C-terminal 
Residues 
E. coli  
GUS      (%) 
Scutellaria 
baicalensis 
GUS
83
      % 
E. coli  
GUS
74
     (%) 
Human 
GUS
47
       (%) 
Acidobacterium 
capsulatum 
GUS
49
       (%) 
Catalytic 
residues 
Glutamates 
(E) 
 
E504Q   0.01 
 
E212A   0.02 
E329A  0.001 
  
E540A   0.001 
E451A   0.005 
 
 
E287G    0.01 
E173G    0.02 
E173A    0.01 
 
Sugar 
Binding 
Residues 
 
 
Y472E    0.1 
N566D   0.04 
R562E   0.03 
R562Q      2 
K568E      0 
K568Q     0 
 
 
Y281A   0.1   
 
 
 
N566S     4 
 
 
K568Q    0 
 
Y504A    0.07 
 
 
Y334F     0.5 
Y243A    0.02  
Y219A     44 
 
 
The experimental results show that mutations lead to loss of activity of enzyme for both PNPG 
and PNPGun. Our studies suggest further mutational studies need to be performed to further 
probe the residues in reactivation of PNPGun as a better substrate. Directed evolution 
experiments with random mutagenesis could be an approach that can be applied
39, 44, 68
. There is 
a further need of finding appropriate mutations required to make PNPGun a good substrate. 
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3.4 pH and Temperature study 
The optimal pH for the activity of Wt GUS was determined by assaying at different pH levels 
using both substrates PNPG and PNPGun. From an ADEPT point of view, enzyme should 
undergo efficient catalysis at physiological pH (pH = 7.4) for catalyzing the reaction. The pH 
study was performed to analyze the enzyme catalysis rate for amide-derivatized substrates. 
Temperature study was also performed to investigate enzyme stability at different temperatures.  
 
 3.4.1 pH optimum study of Wt GUS  
The optimal pH of the Wt GUS was determined at room temperature (24°C) over a pH 
range of 4-9 at every half interval. Kinetic parameters Vmax and Km were determined at each 
interval and the data was measured in duplicate. The enzyme (Wt GUS) was found to be most 
active in pH range 7-8 (Fig 3.19) which was consistent with the previously obtained results using 
PNPG as substrate
52, 68
.   
(A)                                                                              (B)  
                  
Figure 3.19 Relative activities (kcat) of Wt GUS at various pHs.  
Kinetic assays were performed at room temperature. (A) Activity profile with PNPG as substrate over the 
concentration range 0.01 – 3.0 mM. (B) Activity profile with PNPGun as substrate over the concentration 
range 0.01 – 1.0 mM. 
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From the kinetic assays performed at various pH levels, it was found that Km values for 
PNPGun ranged from 0.03-0.08 mM, while Km for PNPG varied from 0.16-1.0 mM.  
(A)                                                                   (B) 
               
 
Figure 3.20 Relative kcat/Km of Wt GUS at various pHs.  
Kinetic assays were performed at room temperature. (A) Relative kcat/Km profile with PNPG as 
substrate. (B) Relative kcat/Km profile with PNPGun as substrate. 
 
The relative catalytic efficiency (kcat/Km) of Wt GUS was found to be mostly efficient in pH 
range 7-8. Results suggest that substrate specificity of GUS for both PNPG and PNPGun was 
highest in the pH range 7-8. In case of PNPG, negatively charged C6 carboxylate interacts with 
positively charged active site. Although in case of PNPGun, substrate specificity of GUS seems 
to be slightly shifted towards the alkaline pH range of 7.5-8.5 which could possibly due to 
neutral C6 carboxamide in PNPGun. The results from this study confirm that GUS is mostly 
active and efficient in the neutral to slightly alkaline pH range. 
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3.4.2 Temperature study of Wt GUS 
 
To investigate protein stability, Wt GUS samples were stored at different temperatures -80°C, -
20°C, 4°C and 23°C (room temperature) for 4 days. The samples were run on SDS-PAGE for 
comparison purposes to evaluate protein degradation (Fig 3.21).  As well, kinetic assays were 
performed on the samples to further probe the effects of temperature on protein activity.  
 
                                 1               2                3               4            5        6 
 
Figure 3.21 SDS-PAGE of GUS stored under different temperatures  
Lane 1: GUS stored at -80°C. Lane 2: GUS stored at -80°C with 50% glycerol. Lane 3: GUS stored at -20°C with 
50% glycerol. Lane 4: GUS stored at 4°C. Lane 5: GUS stored at room temperature. Lane 6: SDS Mol. Wt. Marker.  
 
From the experiment, it was found that the protein samples showed similar activity while stored 
at different temperatures except when stored at room temperature which showed least activity 
(Table 3.10). 
 
kDa  
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 Table 3.10 Kinetic parameters of Wt GUS with PNPG as substrate 
  
Enzyme Temperature 
 
Km (mM) kcat (s
-1
) 
Wt GUS 4°C 0.09 ± 0.03 111 ± 10 
Wt GUS -20°C 0.09 ± 0.01 92 ± 2 
Wt GUS -80°C 0.09 ± 0.01 97 ± 4 
Wt GUS 23°C (Rt*) 0.07 ± 0.01 70 ± 3 
                             * Room temperature 
 
3.5 Cicular Dichroism 
Circular dichroism (CD) spectroscopy is a useful technique in the determination of 
secondary structure of protein samples. It measures differential absorption of left (L) versus right 
handed (R) polarized light (∆A = AL- AR). A CD signal will be generated when L and R 
component are absorbed unequally as it passes through asymmetric molecules
84
. This technique 
is particularly helpful in the determination of secondary structure of mutants when compared to 
the wild type protein
85
. It has also been used investigate structural effects which can arise from 
changing sample conditions such as buffer compositions, temperature and pH. The different 
types of regular secondary structure found in proteins give rise to characteristic CD phenomena 
in the far UV spectrum
86. Peptide bonds in α-helices, β-sheets, β turns and random coils exhibit 
absorption below 240 nm
86
. Secondary structures such as α-helices show negative bands at 222 
nm and 208 nm, and positive band at 193 nm
87, 88. CD spectrum for β-sheets show negative 
bands at 218 nm and positive bands at 195 nm
89
, while disordered protein structure have very 
low ellipticity below 210 nm and negative bands near 195 nm
90
. 
 
Site directed mutagenesis may results in disintegration of secondary structure of protein. To 
verify that mutations have no effect on enzyme secondary structure, CD experiments were 
performed. 
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Circular dichroism spectrums were collected in the far UV region (180-250) which 
corresponds to the peptide bond absorption energy. The data can be used to obtain information 
on the secondary structure content of protein molecules. 
The reduction or elimination of catalytic activity for GUS mutants could be attributed to a 
deleterious change in secondary protein structure. Point mutation to the residues, which are 
elemental in formation of a α-helix, β-strands or β-turns, results in loss of structural integrity of 
protein. As neutral (glutamine) and negatively charged (glutamate) residues were introduced into 
the active site, the disruption of the overall charge could result in disordered secondary structure 
of the protein. As such, examination of the mutated GUS proteins through CD experiments was 
warranted.  
 
Figure 3.22 Cicular dichroism spectrum for Wt GUS and mutants. 
 [ ] corresponds to the molar ellipticity 
 
Wt GUS and its mutants were compared with the wild type protein to confirm mutations made to 
the protein did not have an effect on the secondary structure (Table 3.11 and Fig 3.22).  
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CDNN software was used to deconvolute the data which utilizes a database of known 
protein secondary structure information to determine the percent secondary structure content of 
the sample. Apart from random noise, the accepted error of the analysis of the CDNN software is 
between 1-5% 
91
.  
The percent secondary structure content of the mutants was found to be comparable with Wt 
GUS when examined over the range of 200-260 nm. Overall, the results suggest that the loss of 
activity for the mutants is likely not due to significant changes in protein secondary structure, but 
due to the mutations itself. 
 
Table 3.11 Comparing secondary structure percentage content of wild type GUS and its mutants. 
Secondary  
Structures 
Wt GUS E504Q N566D R562Q R562E K568Q K568E Y472E 
α-helices % 18 18 17 20 17 19 20 20 
β-antiparallel 
% 
23 24 24 21 24 22 21 21 
β-parallel % 5 5 5 5 5 5 5 5 
β-Turn % 18 19 19 18 19 18 18 18 
Random Coil 
% 
35 35 35 35 35 36 35 35 
Total Sum % 99 101 100 99 100 100 99 99 
 
3.6 Isothermal Titration Calorimetry  
Isothermal titration calorimetry (ITC) has been widely used in study of biomolecular 
interactions such as protein-protein
92
 and protein ligand interactions
93
. The fundamental premise 
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behind ITC is that heat change is always associated with these types of interactions. This 
observed heat change determines the affinity of the reaction
94
. Thermodynamic parameters are 
characterized depending on the stoichiometry of the reaction (n), enthalpy (∆H), and binding 
affinity (Ka). Subsequently both entropy (∆S) and free energy (∆G) can be calculated from the 
measurable parameters
93
. In a typical experiment, reactant (ligand) is titrated against the protein 
which is present in the reaction cell. Each injection produces measurable quantity of heat (Q) 
which corresponds to the signal from the baseline. The heat is directly proportional to quantity of 
ligand binding to the protein in each injection. The binding enthalpy is calculated by integrating 
signal from baseline (area under curve) over the duration of each peak 
95
 .  
An ITC instrument consists of two identical cells; a reference cell and a sample cell, composed 
of a highly efficient thermal conducting material (gold) surrounded by an adiabatic jacket
92
. 
Sensitive thermocouple circuits detect temperature differences between the two cells and 
between the cells and the jacket (Fig 3.23). Heaters located on both cells and the jacket are 
activated when necessary to maintain identical temperatures between all components
92
. 
 
 
Figure 3.23 Schematic diagram of an ITC instrument. 
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The macromolecule being investigated is placed in the reaction cell and the reference cell 
contains only buffer. Constant power is applied to both reference and reaction cell to maintain 
constant temperature throughout the course of the reaction. This produces the baseline signal. 
Heat is taken up or released in a reaction upon ligand injections. This results in a change in 
temperature which is maintained by applying more power to the cells to keep the temperature 
constant. An exothermic reaction is based on binding affinity of ligand towards the protein. The 
initial ligand injections result in relatively larger peaks due to higher heat production. As ligand 
concentration increases in the cell, due to subsequent injections, protein saturation occurs and 
less heat is released. After saturation of protein, further injections generate peaks of similar 
magnitude (smaller), which is equivalent to the heat of dilution of ligand in buffer. A control 
experiment is also run by injecting ligand in the buffer without protein, to measure heat of 
dilution of ligand
93
. Each experiment consists of 10-20 injections of ligand depending upon the 
saturation rate of the macromolecule being investigated.  
The ITC technique is very useful in determining ligand binding or protein interaction studies. 
Enthalpy driven reactions can be easily quantified, making it more versatile and sensitive 
towards measuring the binding isotherm of a reaction. ITC plays a vital role in ligand binding 
studies
96
, especially in cases where no enzyme activity is showed by the amino acid mutations, 
ITC predicts the binding of the ligand with the enzyme. 
ITC is a biophysical technique which uses heat as a signal to measure enthalpy changes 
directly. A high signal to noise ratio is essential for correct determination of enthalpy and 
binding affinity.  According to Wiseman et al., the shape of a binding isotherm, for a simple one 
site model, changes according to the product of the association constant (Ka) and the 
(macromolecular) receptor concentration [P], which they referred to as the c value
97
.  
                                                                         (14) 
For c values higher than 10, the binding isotherm tends to be sigmoidal in shape. Experimentally 
determined  c value have an optimal  range from 10-500 for good binding isotherm while c 
values lower than 10 are indicative of poor isotherm shape 
97
. In the case of low affinity systems, 
the protein concentration must be high enough to achieve reasonable c value to generate 
sufficient binding isotherm for extraction of thermodynamic parameters.  
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Turnbull and Daranas validated that in the case of low c values if the stoichiometry of the 
reaction is known and a high signal to noise ratio and sufficient portion of binding isotherm is 
measured, then  thermodynamic parameters like enthalpy ( ∆H) and binding constant (Ka) can be 
determined accurately 
98
. Advancement in ITC instrumentation in the last 10 years has allowed 
for weaker protein-ligand interactions which have correspondingly low c values, to be measured 
with increased accuracy
98
.  
Injections were made at an interval of 150-200 s while equilibrium was achieved within 150 s. 
Samples were degassed for at least an hour, as even a very small air bubble increases the noise 
level and the signal to noise ratio greatly perturbed.  
The determination of thermodynamic parameters depends on the fitness of binding curve. A 
higher degree of sigmoidal curve yields more accurately thermodynamic parameters. Inaccurate 
protein:ligand stoichiometry can often arise due to impurity in protein samples or undetermined 
concentrations. 
  Isothermal titration calorimetry was performed on binding of glucuronic acid with Wt GUS 
to establish comparative enthalpic and entropic parameters. GUS substrates are specifically 
glucuronide derivatives. The glucuronic acid portion is vital for substrate recognition and hence 
catalysis.  As previously discussed, mutational kinetic analysis suggested the importance of 
K568 for catalytic activity of PNPG.  However, the data does not preclude substrate binding, 
merely that a productive binding mode was not achieved. ITC measurements were conducted to 
further probe the binding of the recognition portion of the substrate, that being glucuronic acid, 
with both K568Q and K568E mutants.  
3.6.1. ITC derived thermodynamic parameters for Glucuronic acid  
 
Figure 3.24 Ligand used in ITC experiments is Glucuronic acid (GA)  
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Glucuronic acid (GA) (Fig 3.24) was used to probe binding towards GUS and to establish 
enthalpic and entropic contributions. Experiments were conducted at 25°C and samples were 
diluted for optimizing better signal to noise ratio. The Kd for GA binding was determined to be 
3.7 mM, which agrees well with the Ki (5.6 mM) determined kinetically. The stoichiometry for 
protein and inhibitor was shown to be 1.0 using an independent model.  The enthalpic (∆H) 
contribution for binding was found to be -16.78 kJ/mol and entropic (T∆S) contribution was 
determined to be -2.8 kJ/mol. These results indicate that GA binding was more enthalpy driven 
while being disfavored by entropy (Table 3.12 and Fig 3.25).  
 
Figure 3.25 Isothermal titration calorimetry analysis of Wt GUS with Glucuronic acid.  
Top panel shows the raw data for 12 injections (4 μL) of GA (10 mM) into buffered solution Wt GUS (0.29 mM). 
Bottom panel shows the fit to an independent model from Nano Analyze provided by TA instruments. 
 
To investigate binding of GA with K568 mutants, ITC experiments were conducted 
under similar condition using similar concentrations of protein and ligand. Titration of GA into 
buffered solution of either GUS K568Q or K568E produced successive peaks of similar 
magnitude throughout the entire experiment (Fig 3.26 and 3.27). As a control experiment, 
Molar Ratio 
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titration of GA into the same buffer without protein produced heats of dilution of similar 
magnitude to those observed for when K568Q or K568E were present. As such, the data 
indicates that GA does not bind to either of the K568Q or K568E GUS mutants within the 
measureable limits of the instrument. Ultimately, the results reveal the importance of the K568 
residue to binding of the recognition portion (GA) of the substrate.  
 
Figure 3.26 Isothermal titration calorimetry analysis of GUS K568E with Glucuronic acid. 
Top panel shows the raw data for 12 injections (4 μL) of GA (10 mM) into buffered solution GUS K568E (0.27 
mM). Heat of dilution was subtracted. Bottom panel shows poor fit to an independent model from Nano Analyze 
provided by TA instruments 
 
One of the parameters which can be adjusted to improve measurable signal is protein 
concentration. Achieving enough higher concentration to measure binding is difficult in 
biological systems. Efforts were made to achieve higher concentrations of protein resulted in 
protein precipitation and could not be resolved.  
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Figure 3.27 Isothermal titration calorimetry analysis of GUS K568Q with Glucuronic acid. 
Top panel shows the raw data for 22 injections (2 μL) of GA (10 mM) into buffered solution GUS K568Q (0.29 
mM). Heat of dilution was subtracted .Bottom panel shows poor fit to an independent model from Nano Analyze 
provided by TA instruments 
3.6.2. Thermodynamic parameters of Wt GUS with Glucaro-δ-lactam  
Best inhibitors for glycosidases (glycoside hydrolase) are the ones that mimic the 
transition state during the substrate binding event 
99
. Several substrate analogues were tested 
earlier to mimic the transition state in the substrate binding event including one of the known 
inhibitor against E.coli GUS is GDL (Fig 3.28), inhibiting strongly in the micromolar range 
51, 96
. 
X ray structure of E. coli GUS bound GDL showed strong interaction with the nearby residues 
 
Figure 3.28 Ligand used in ITC experiments is potassium salt of glucaro-δ-lactam (GDL)  
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as discussed above. Dissecting thermodynamic parameters for GDL binding towards GUS 
revealed that the virtuosity of GDL binding derived not only from large enthalpic contributions (-
17.5 kJ/mol) but also from large positive entropy (14.4 kJ/mol) (Table 3.12 and Fig 3.29). The 
Kd for binding was determined to be 2.7 μM, which is roughly in agreement with Ki value (7.7 
μM) published previously 51. The enthalpic and entropic contribution made by GDL is in 
agreement with the previous published ITC studies by similar glycosidase inhibitor analogues
96, 
100
.   
 
Figure 3.29 Isothermal titration calorimetry analysis of Wt GUS with GDL.  
Top panel shows the raw data for 14 injections (2 μL) of GDL (500 μM) into buffered solution t GUS (50 μM). 
Bottom panel shows the fit to an independent model from Nano Analyze provided by TA instruments 
Although it is likely that GDL binding is similar to the glucuronic acid, it is not known as there is 
no X ray structure of E. coli GUS with GA.  The ITC on native GUS compared to K568 mutants 
will give us an idea if that residue is important to GDL binding.  And if there is an effect on GDL 
binding due to mutation on K568, this effect could be seen with substrate binding. The binding 
of GDL will examine the importance of K568 residue.  
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3.6.3. Thermodynamic parameters of GUS K568E and K568Q with Glucaro-δ-lactam  
The known inhibitor, GDL, was used to explore binding with mutants K568E and 
K568Q. Experimental result revealed that GDL binds to the mutants with a similar binding 
constant as it does to wild type protein. The Kd value for K568E and K568Q were 2.4 μM and 
7.7 μM respectively (Table 3.12 and Fig 3.30, 3.31).  
 
Figure 3.30 Isothermal titration calorimetry analysis of GUS K568E with GDL.  
Top panel shows the raw data for 15 injections (3 μL) of GDL (500 μM) into buffered solution GUS K568E (50 
μM). Bottom panel shows the fit to an independent model from Nano Analyze provided by TA instruments 
As compared to Wt GUS, the mutant binding event was driven less by enthalpy (K568E: 
-6.4 kJ/mol and K568Q: -2.6 kJ/mol) and more by entropic (K568E: 25.6 kJ/mol and K568Q: 
26.5 kJ/mol) contributions. The lower mutant enthalpies suggest K568 plays an important role in 
making strong interactions with the inhibitor. In regard to the entropy contributions, the mutants 
favored the overall binding of ligand to a greater extent which could signify an increased 
removal of solvent upon ligand binding.  
High enthalpy values are often observed due to the formation of hydrogen bonds, van der Waals 
forces and electrostatic interactions. Deconvolution of entropic factors is more complicated due 
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to solvation effects of both protein and ligand and the associated rotational and translational 
degrees of freedom of both protein and ligand
101
. In general positive entropy is encountered 
when solvent molecules are released during the ligand binding event, while negative entropy 
results due to loss of translation, vibrational and rotational degree of freedom
101
. Entropic gain is 
due to the fact that water molecules no longer remain positionally confined. Upon binding to the 
protein, the ligand replaces the water molecules occupying the binding site and this event leads 
to break several hydrogen bonds with water molecules
101
. Enthalpy and entropy values 
compensate each other for a binding event.  
In case of K568E and K568Q, replacement of water molecule results in direct interaction 
of ligand with protein. Steric restrictions play vital role, as a result, some parts of conformation 
space of ligand remain inaccessible. Ultimately the dissociation constant (Kd) for GDL binding 
within both K568 mutants and Wt protein are similar which suggests enthalpy contributions are 
compensated by entropy 
 
Figure 3.31 Isothermal titration calorimetry analysis of GUS K568Q with GDL. Top panel 
shows the raw data for 15 injections (3 μL) of GDL (1 mM) into buffered solution GUS K568Q (100 μM). Bottom 
panel shows the fit to an independent model from Nano Analyze provided by TA instruments 
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Table 3.12 Isothermal titration calorimetry of Wt GUS, K568E and K568Q with glucuronic acid 
(GA) and Glucaro-δ-lactam (GDL).  Each experiment was performed in triplicate at 25°C. 
 
Enzyme Ligand Kd (μM) ΔG (kJ/mol) ΔH (kJ/mol) TΔS (kJ/mol) 
GUS GA (3.7 ± 1) x 10
3 
-13.8 ± 0.8 -16.78 ± 5  -2.8 ± 6 
GUS GDL 2.7 ± 1.5  -31.9 ± 1.4 -17.5 ± 3.3 14.4 ± 4.6 
K568E GDL 2.4 ± 0.2  -32.0 ± 0.3  -6.4 ± 2.7 25.6 ± 2.8 
K568Q GDL 7.7 ± 1.8  -29.1 ± 0.6  -2.6 ± 1.0 26.5 ± 1.6 
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4 CONCLUSION AND FUTURE WORK 
4.1 Conclusion: 
The observations of this research can be summarized as: 
1. Glucuronide to glucuronamide modification reduced the overall turnover rate, which was 
consistently observed over p-nitrophenyl, phenyl and 4-methylumbelliferyl derivatives 
 
Wild-type GUS is still active on PNPGun. Most surprising is the low Michaelis constant, 
suggesting substrate binding interactions are not compromised by the substitution of the 
carboxyl group with a carboxamide. There is a 10-fold reduction in the substrate 
specificity. 
 
The substrate specificity of Wt GUS for phenyl-β-D-glucuronamide (PGun) is 30 fold less 
than Phenyl-β-D-Glucuronide (PG). 
 
4-Methylumbelliferyl-β-D-glucuronamide (MUGun) has 15 fold reduction in substrate 
specificity compared to MUG (4-methylumbelliferyl-β-D-glucuronide), verified by both 
UV spectroscopy and fluoro-spectroscopy 
 
2. p-Nitrophenyl β-D-glucopyranoside (PNPGlu) is not a substrate for GUS and showed 
trace activity and very weak inhibition with Ki = 5 mM. 
 
3. S-Glucuronides such as p-nitro-thio-phenyl β-D-glucuronide (PNSPG) and thio-phenyl β-
D-glucuronide (PGS) are not good substrates for GUS. PNSPG substrate specificity is 
1500 fold less, compared to PNPG, while PGS is neither a substrate nor an inhibitor. 
 
4. As expected, site-directed mutants which make the active site less positively charged, 
either by replacing a positively charged residue with neutral glutamines, or by replacing a 
neutral residue with negatively charged glutamates, results in an enzyme with much 
lower activity. 
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All mutations reduced the activity of the enzyme to less than 2%, residues Y472, R562, 
K568, N566D are involved in forming hydrogen bonds with the C6 carboxylate of 
PNPG. All mutations were deleterious as expected.   
 
5. The mutations also lowered or abolished activity on PNPGun. 
 
Subsequently mutations also effected the interactions between the C6 carboxamide and 
respective residues in the near vicinity, resulting in no activity. 
 
From all above results it is concluded that   
1. A negatively-charged substrate is not required for GUS-catalyzed hydrolysis of the 
glycosidic bond. 
This has been demonstrated by using neutral glucuronamide derivatives with different 
leaving groups and the amide derivatives are still acting as substrates albeit with low 
turnover rate. 
2. Alterations to the active site have a similar effect on glucuronic acid and Gun substrates 
 
Site directed mutagenesis results in reduced activity of enzyme against PNPG which was 
expected, but subsequent mutations also reduced the activity towards PNPGun. 
 
3. Further mutational studies are required to investigate substrate selectivity exhibited by 
GUS 
 
Our initial hypothesis was that ionic interactions between negatively charged C6 
carboxylate and positively charged residues Arg 562 and Lys 568 in enzyme bound 
structure are important for activity. Substituting a neutral carboxamide at the C6 position 
still acts as a substrate and in fact, binding interactions are not compromised to larger 
extent, suggesting further understanding of enzyme structure function relationship is 
required. The role of residues near the C6 carboxyl group of glucuronide such as Y469, 
Y468, K567, D163, and W549 still need to be explored. 
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A glucuronamide derivatized substrate proved to be a poor substrate for Wt GUS 
supported by the kinetics results. There is still a further need of finding appropriate 
mutations required to make glucuronamide a better substrate for the mutated version of 
GUS.  
Purified Wt GUS was supplied to colleagues for the crystallization trials, which were not 
successful at the time of writing this thesis. So far, there is no crystal structure of GUS 
with substrate has been obtained yet. The 3-dimensional structure of GUS with substrate 
bound will be helpful in understanding this protein and would assist in modifying 
substrate specificity.  
 
 
 
4.2 Future Work 
Residues near the active site are frequently involved in substrate specificity and may improve 
kinetics. There is a further need of finding appropriate mutations required to make PNPGun a 
good substrate. PNPGun still binds to the Wt GUS and shows activity which suggests further 
improvement in substrate modification are required so that native enzyme will not be able 
recognize the substrate. Further substrate modification could be implementing methyl or ethyl 
ester at C6 position. 
Limited mutations were not successful to unravel the residues roles in substrate specificity and in 
regaining activity against PNPGun as a better substrate. Point mutations to residues Y472, Y468, 
D163, and N566 to positively charged residues such as arginine or lysine will make the active 
site more positively charged and could be beneficial.  
So far there is no GUS structure with substrate is available, X ray crystal structure of GUS with 
substrate would open the gates in uncovering the residues roles responsible for substrate 
interactions. This would also help in further understanding of structure function relationship of 
GUS. 
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Kinetic study needs to be performed on human GUS using amide derivatized substrate to verify 
if the effects are the same as in the case of E. coli GUS. Once the base research goal is 
established, the principles will be translated to human GUS to reduce the chance of 
immunogenic response for ADEPT. 
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